Objective The world faces a growing epidemic of antimicrobial resistance (AMR); however, only two new classes of antibiotics have been brought to the market in the last 30 years. The discovery and development of new antibiotics is essential to maintain medical advances but poses significant scientific, clinical, and financial challenges, particularly for antibiotics active against Gram-negative bacteria (such as E. coli). Such bacteria have effective barriers against drugs, making treatment difficult, resistance likely and development costs and risks high. In addition, any new antibiotics brought to the market would likely be used cautiously to delay the development of resistance, adding an additional financial challenge in recouping the development costs. The O’Neill Report on AMR identifies diagnostics as critical to the battle against antibiotic resistance.This innovation action, BreathSpec, proposes a viable solution to the global problem of AMR through the final developmental stages of an existing diagnostic device, which will allow a rapid, binary decision to be made on the need for antibiotic treatment, and which with suitable optimisation will allow further differentiation and stratification to take place. The Innovation Action includes technical developments to optimise its function, data acquisition for the development of the decision making analytical function and clinical validation.It addresses these issues by producing reliable identification and quantification of key signature volatiles present in exhaled breath. It provides a non-invasive method for monitoring the volatile organic compounds present in an individual’s exhaled breath (and subsequently the blood) and has long been recognised as having significant utility as a clinical test that can be used for early disease detection and monitoring, and potentially to diagnose specific bacterial infections for better, more targeted use of existing antibiotics. Fields of science medical and health sciencesclinical medicinepneumologynatural scienceschemical sciencesorganic chemistryvolatile organic compoundsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepathologymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EC - Horizon 2020 Framework Programme Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2. - PRIORITY 'Industrial leadership' Topic(s) FTIPilot-01-2016 - Fast Track to Innovation Pilot Call for proposal H2020-FTIPilot-2016 See other projects for this call Sub call H2020-FTIPilot-2016-1 Funding Scheme IA - Innovation action Coordinator IMSPEX DIAGNOSTICS LIMITED Net EU contribution € 1 141 700,00 Address TY MENTER, NAVIGATION PARK, RCT CF45 4SN Abercynon United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Wales West Wales and The Valleys Central Valleys Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 631 500,00 Participants (4) Sort alphabetically Sort by Net EU contribution Expand all Collapse all G.A.S. GESELLSCHAFT FUR ANALYTISCHESENSORSYSTEME M.B.H. Germany Net EU contribution € 507 150,00 Address OTTO HAHN STRASSE 15 44227 Dortmund See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Nordrhein-Westfalen Arnsberg Dortmund, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 724 500,00 STATISTICAMEDICA LIMITED Ireland Net EU contribution € 462 087,50 Address 26 BELARMINE COURT ENNISKERRY ROAD STEPASIDE D18 DUBLIN See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 660 625,00 REDKNIGHT CONSULTANCY LTD United Kingdom Net EU contribution € 116 287,50 Address 21 THE DAIRY CF728TT PONTYCLUN See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Wales West Wales and The Valleys Central Valleys Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 166 125,00 THE UNIVERSITY OF WARWICK United Kingdom Net EU contribution € 140 422,50 Address Kirby Corner Road - University House CV4 8UW Coventry See on map Region West Midlands (England) West Midlands Coventry Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 140 422,50
